Evidence map›Paper›PMID 29243394›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2018

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

M Haas, A Loupy, C Lefaucheur, C Roufosse, D Glotz, D Seron, B J Nankivell, P F Halloran, R B Colvin, Enver Akalin and 19 more

3 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 477 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
477citing papers in PubMed, 5 pooled it
79.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04444843 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

A Multicenter Clinical Trial: Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2021 to 2023Enrolled300ConditionsKidney Transplant RecipientsArmsMycophenolate Mofetil Capsules
NCT05306795 unknown statusnot on this map

Development, Application, and Validation of a Comprehensive Classification Automation System for Allograft Precision Diagnostics in Adult and Pediatric Kidney Transplant Biopsies

TypeobservationalSponsorParis Translational Research Center for Organ TransplantationRan2016 to 2022Enrolled4,000ConditionsKidney Transplant Rejection, Pathology
NCT05727709 unknown statusnot on this mapstarted 2023, after this paper: background citation

Dynamic Changes of Torquetenovirus Load in Chinese Renal Transplant Recipients During Immunosuppressive Therapy: A Double-blind Multicenter Prospective Observational Cohort Study

TypeobservationalSponsorTongji HospitalRan2023 to 2024Enrolled220ConditionsKidney Transplant Rejection, Kidney Transplant Infection, Virus, Immunosuppression
3 · Its place in the literature

Who cites it

477 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,013 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article

417 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 17 institutions in 9 countries.

M HaasDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
A LoupyParis Translational Research Center for Organ Transplantation, INSERM U970 and Necker Hospital, University Paris Descartes, Paris, France.
C LefaucheurParis Translational Research Center for Organ Transplantation and Department of Nephrology and Transplantation, Hopital Saint Louis, Université Paris VII and INSERM U 1160, Paris, France.
C RoufosseDepartment of Medicine, Imperial College London and North West London Pathology, London, UK.
D GlotzParis Translational Research Center for Organ Transplantation and Department of Nephrology and Transplantation, Hopital Saint Louis, Université Paris VII and INSERM U 1160, Paris, France.
D SeronNephrology Department, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
B J NankivellDepartment of Renal Medicine, Westmead Hospital, Sydney, Australia.
P F HalloranAlberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0003-1371-1947
R B ColvinDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Enver AkalinMontefiore-Einstein Center for Transplantation, Montefiore Medical Center, Bronx, NY, USA.
N AlachkarDepartment of Medicine, Section of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
S BagnascoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Y BouatouParis Translational Research Center for Organ Transplantation, INSERM U970 and Necker Hospital, University Paris Descartes, Paris, France.ORCID 0000-0003-3697-3886
J U BeckerInstitute of Pathology, University Hospital of Cologne, Cologne, Germany.
L D CornellDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
J P Duong van HuyenParis Translational Research Center for Organ Transplantation, INSERM U970 and Necker Hospital, University Paris Descartes, Paris, France.
I W GibsonDepartment of Pathology, University of Manitoba, Winnipeg, Canada.
Edward S KrausDivision of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
R B MannonDivision of Nephrology, Department of Medicine, University of Alabama School of Medicine, Birmingham, AL, USA.
M NaesensDepartment of Microbiology and Immunology, University of Leuven & Department of Nephrology, University Hospitals Leuven, Leuven, Belgium.
V NickeleitDivision of Nephropathology, Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
P NickersonDepartment of Internal Medicine and Immunology, University of Manitoba, Winnipeg, Canada.
D L SegevDepartment of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
H K SinghDivision of Nephropathology, Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
M StegallDepartments of Surgery and Immunology, Mayo Clinic, Rochester, MN, USA.
P RandhawaDivision of Transplantation Pathology, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
L RacusenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
K SolezDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
M MengelDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Johns Hopkins University · USDélégation Paris 5 · FRUniversity of Alberta · CAInserm · FRMayo Clinic in Arizona · USUniversity of Manitoba · CAUniversity of North Carolina at Chapel Hill · USAlbert Einstein College of Medicine · USCedars-Sinai Medical Center · USHarvard University · USKU Leuven · BENorth West London Pathology · GBUniversitat Autònoma de Barcelona · ESUniversity Hospital Cologne · DEUniversity of Alabama · USUniversity of Pittsburgh · USWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell-mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

Indexed as

Postoperative ComplicationsGraft RejectionHigh-Throughput Nucleotide SequencingHumansInflammationIsoantibodiesKidney TransplantationPrognosisResearch ReportT-LymphocytesIsoantibodiesclassification systems: Banff classificationkidney transplantation/nephrologymolecular biologypathology/histopathologyrejectiontranslational research/science

Identifiers

PMID29243394
PMCPMC5817248
OpenAlexW2774126255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.